Digital PCR Market to Gain Momentum due to Rising Prevalence of Infectious Diseases
The global digital PCR market size is forecast to reach USD 799.1 million by 2026, attributed to the increasing prevalence of infectious diseases and genetic disorders worldwide. Digital PCR is the biotechnological advancement of conventional PCR and provides a reproducible and sensitive method of measuring the amount of RNA or DNA in a sample. Fortune Business Insights discusses the market and its growth trajectories in a recently published report titled, “Digital PCR Market Size, Share & Industry Analysis, By Type (Droplet Digital PCR, Chip-based Digital PCR, and Others), By Product (Instruments and Reagents & Consumables), By Indication (Infectious Diseases, Oncology, Genetic Disorders, and Others), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Industries, Diagnostic Centers, and Academic & Research Organizations), and Regional Forecast, 2019-2026”.
List of prominent companies that are operating in the Digital PCR are:
- Qiagen
- JN Medsys
- Merck KGaA
- Fluidign Corporation
- Stilla Technologies
- Thermo Fisher Scientific Inc.
- Sysmex Inostics
- Bio-Rad Laboratories Inc.
- Other Players
“Rise in Prevalence of Genetic Disorders to Aid in Expansion of Market”
The increasing prevalence of infectious and genetic diseases is a major digital polymerase chain reaction market growth driver. In addition to this, the advancement in medical technology and introduction of innovative devices for therapeutic purposes will also aid in expansion of the market in the coming years. These innovative devices include crystal dPCR, beam dPCR chip-based digital PCR, and droplet digital PCR.
On the other side, high cost of digital polymerase chain reaction installation may pose a major challenge to the market growth. This, coupled with the lack of awareness about the availability of treatment options, especially in developing and under-developed nations, may hamper the overall market in the coming years. Nevertheless, the gradual shift towards chip-based dPCR from droplet dPCR by healthcare providers is expected to boost the market in the coming years.
“Increasing Prevalence of Genetic Disorders to help Asia Pacific Register Faster CAGR by 2026”
As per geographical segmentation, North America earned the largest digital polymerase chain reaction market share with a revenue of USD 96.5 million earned in 2018. This is owing to the high prevalence and diagnosis rate of infectious disease and the availability of better healthcare facilities in the region. In addition, there is high awareness among people about the availability of advanced dPCR devices as treatment options in the developed nations of the region. Furthermore, the increasing number of various cancer cases and metabolic diseases are also boosting the regional market.
“Bio-Rad, Sysmex Inostics, and Thermo Fisher to Hold Dominant Shares with Diverse Portfolio”
The global digital PCR market is consolidated in nature owing to the presence of many players. Companies such as Thermo Fisher Scientific Inc., Sysmex Inostics, and Bio-Rad Laboratories, Inc., are holding majority shares in the market on account of their diverse portfolio of chip-based digital PCR and droplet digital PCR and continuous launch of innovative technologies by these companies at large. Other players operating in this market are emphasizing on mergers and acquisitions, contracts and agreements, or other collaborative methods to attract high digital PCR market revenue and attain a significant position in the market in the coming years.
Author’s Bio: Name- Aman Singh Gandhi
Aman is presently working as a content writer at Fortune Business Insights. His key focus is to deliver quality content to his audience. He specializes in blog writing, articles, and press releases. As a writer, he believes in learning and exploring different areas to communicate with his readers vividly.
